| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAF15 |
| Uniprot No | Q92804 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 148-406aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSSYHSQRE NYSHHTQDDR RDVSRYGEDN RGYGGSQGGG RGRGGYDKDG RGPMTGSSGG DRGGFKNFGG HRDYGPRTDA DSESDNSDNN TIFVQGLGEG VSTDQVGEFF KQIGIIKTNK KTGKPMINLY TDKDTGKPKG EATVSFDDPP SAKAAIDWFD GKEFHGNIIK VSFATRRPEF MRGGGSGGGR RGRGGYRGRG GFQGRGGDPK SGDWVCPNPS CGNMNFARRN SCNQCNEPRP EDSRPSGGDF RGRGYGGERG YR |
| 预测分子量 | 30 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TAF15重组蛋白的3篇代表性文献及其摘要概括：
---
1. **文献名称**: *TAF15 regulates transcriptional elongation through phase separation*
**作者**: Smith, J., Barabási, S., et al.
**摘要**: 本研究通过重组TAF15蛋白揭示了其在转录延伸中的作用，发现其通过液-液相分离(LLPS)招募RNA聚合酶II，调控基因表达，并证明其C端低复杂度结构域是相分离的关键区域。
---
2. **文献名称**: *Recombinant TAF15 exhibits prion-like aggregation properties in neurodegenerative disease models*
**作者**: Lee, A., Taylor, J.P., et al.
**摘要**: 该研究利用重组TAF15蛋白在体外和细胞模型中证明其具有类似朊病毒的聚集特性，并发现其在肌萎缩侧索硬化症(ALS)患者神经元中异常聚集，可能与神经退行性病变相关。
---
3. **文献名称**: *Structural and functional analysis of TAF15 in RNA binding and splicing regulation*
**作者**: Müller, C.W., Storz, G., et al.
**摘要**: 通过重组TAF15蛋白的晶体结构解析，揭示其RNA识别基序(RRM)与特定RNA序列的相互作用机制，并证明其通过调控pre-mRNA剪接参与癌症相关基因表达失调。
---
**备注**：以上文献信息为示例性概括，实际文献需通过PubMed/Google Scholar检索关键词“TAF15 recombinant protein”或“TAF15 purification”获取具体信息。近年研究多聚焦于TAF15在相分离、神经退行性疾病及癌症中的分子机制。
TAF15 (TATA-box binding protein-associated factor 15) is a member of the TET family of RNA-binding proteins, which also includes FUS and EWSR1. It features conserved N-terminal prion-like low-complexity domains (LCDs) and C-terminal RNA recognition motifs (RRMs), enabling its dual role in transcription regulation and RNA processing. Originally identified as a component of the TFIID complex in transcription initiation, TAF15 interacts with RNA polymerase II and mediates chromatin remodeling, spliceosome assembly, and DNA damage response. Its LCD domain facilitates liquid-liquid phase separation, critical for forming membraneless organelles like stress granules.
TAF15 is implicated in cancers (e.g., leukemia, sarcomas) through chromosomal translocations that generate oncogenic fusion proteins. In neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), cytoplasmic TAF15 aggregates are observed, suggesting parallels to FUS/TDP-43 proteinopathies. These aggregates may disrupt RNA metabolism and nucleocytoplasmic transport.
Recombinant TAF15 proteins are produced via bacterial (e.g., E. coli) or mammalian expression systems, often tagged with fluorescent or affinity markers for functional studies. They enable in vitro analysis of phase separation kinetics, RNA-binding specificity, and protein-protein interactions. Researchers use these tools to investigate TAF15’s pathological aggregation mechanisms and screen therapeutic compounds targeting its aberrant behavior. Structural studies of recombinant TAF15 variants also clarify how mutations affect its solubility and subcellular localization, providing insights into disease pathogenesis.
×
